You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》市傳維昇藥業今年內在港上市 籌最多3億美元
阿思達克 01-27 14:43
據路透旗下《IFR》引述消息指,維昇藥業計劃今年內在港上市,集資規模2億至3億美元。維昇藥業為內地內分泌相關治療領域生物科技公司,剛於1月9日宣布完成1.5億美元B輪融資。該輪融資由紅杉中國基金領投,奧博資本,夏爾巴投資,Cormorant, HBM Healthcare Investments, 鼎豐生科資本,Logos Capital,晨嶺資本跟投。現有股東Ascendis Pharma A/S(ASND.US),維梧資本(VIVO Capital),Sofinnova Investments該輪持續加碼。

公司於2018年成立,由Ascendis Pharma A/S與維梧資本領導的聯合投資人共同創立,Sofinnova Investments參與首輪投資。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account